Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort
Louise von Hess Medical Research Institute
Lancaster General Research Institute

      The purpose of this study is to evaluate whether patients post PCI receiving clopidogrel who
      are carriers of at least one CYP 2C19 loss-of-function allele may achieve improved
      pharmacodynamic efficacy of clopidogrel when treated with the CYP 2C19 enzyme inducing agent,
      St. John's wort, as compared with placebo.

      Hypothesis

        1. Reduced platelet reactivity is present in patients receiving St. John's wort as compared
           to placebo when utilized in combination with clopidogrel

        2. The combination or St. John's wort and clopidogrel results in enhanced platelet
           inhibition
    
Drug